Companies › Avistone Biotechnology
5 active drug programs in 14 registered trials: 8 Phase 1, 6 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PLB1004 EGFR inhibitor | EGFR | Phase 2 | Non-Small-Cell Lung Cancer; NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer | Nov 2026 |
| Vebreltinib MET inhibitor | MET | Phase 2 | Non-Small-Cell Lung Cancer; Clear Cell Sarcoma (CCS) | Dec 2026 |
| ANS014004 | – | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Apr 2027 |
| ANS03 ROS1 and NTRK tyrosine kinase inhibitor | ROS1, NTRK | Phase 1 | Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration | Dec 2027 |
| ANS02 | – | Phase 1 | Non-Small Cell Lung Cancer | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07336732 | PLB1004 | Phase 2 | Non-Small-Cell Lung Cancer | Oncology | Nov 2026 |
| NCT06015503 | PLB1004 | Phase 2 | NSCLC (Non-small Cell Lung Cancer) | Oncology | Dec 2026 |
| NCT06343064 | PLB1004 | Phase 1 | Non-Small-Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06343064 | Vebreltinib | Phase 1 | Non-Small-Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06307795 | ANS014004 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Apr 2027 |
| NCT07153887 | Vebreltinib | Phase 2 | Clear Cell Sarcoma (CCS) | Oncology | Jul 2027 |
| NCT06574347 | PLB1004 | Phase 2 | Non-Small-Cell Lung Cancer | Oncology | Jul 2027 |
| NCT06574347 | Vebreltinib | Phase 2 | Non-Small-Cell Lung Cancer | Oncology | Jul 2027 |
| NCT07655622 | Vebreltinib | Phase 1 | Non-Small-Cell Lung Cancer | Oncology | Dec 2027 |
| NCT06716138 | ANS03 | Phase 1 | Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration | Oncology | Dec 2027 |
| NCT06328439 | ANS014004 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Dec 2027 |
| NCT06046495 | PLB1004 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Feb 2028 |
| NCT06827145 | Vebreltinib | Phase 2 | Non-Small-Cell Lung Cancer | Oncology | Sep 2028 |
| NCT07538804 | ANS02 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Jun 2029 |
AstraZeneca Shanghai Henlius Biotech Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Betta Pharmaceuticals Allist Pharmaceuticals Dizal Pharmaceuticals Pfizer Pierre Fabre Medicament
Nanjing Sanhome Pharmaceutical Jiangsu Alphamab Biopharmaceuticals Pierre Fabre Medicament Teligene US Xuanzhu Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.